Bio-Techne to acquire Asuragen

Create PDF

Asuragen CEO, Matt McManus, will join the Bio-Techne team to continue to lead the legacy Asuragen business as well as the integration process. Bio-Techne anticipates the acquisition to close in the fourth quarter of its fiscal 2021.

Bio-Techne, 612-379-2956
Asuragen, 512-681-5200